Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, Ferreira H, Hughes J, Joseph L, Kock Y, Letsaolo V, Maartens G, Meintjes G, Ngcamu D, Okozi N, Padanilam X, Reuter A, Romero R, Schaaf S, Te Riele J, Variava E, van der Meulen M, Ismail F, Ndjeka N. Ismail NA, et al. Among authors: kock y. Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780706
Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.
Mohr-Holland E, Reuter A, Furin J, Garcia-Prats A, De Azevedo V, Mudaly V, Kock Y, Trivino-Duran L, Isaakidis P, Hughes J. Mohr-Holland E, et al. Among authors: kock y. EClinicalMedicine. 2020 Mar 3;20:100290. doi: 10.1016/j.eclinm.2020.100290. eCollection 2020 Mar. EClinicalMedicine. 2020. PMID: 32154506 Free PMC article.
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P. Mohr E, et al. Among authors: kock y. Eur Respir J. 2018 Jun 14;51(6):1800017. doi: 10.1183/13993003.00017-2018. Print 2018 Jun. Eur Respir J. 2018. PMID: 29724920 Free PMC article.
Early mortality during rifampicin-resistant TB treatment.
Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick C, Kock Y, Cox V, Furin J, Cox H. Mohr-Holland E, et al. Among authors: kock y. Int J Tuberc Lung Dis. 2022 Feb 1;26(2):150-157. doi: 10.5588/ijtld.21.0494. Int J Tuberc Lung Dis. 2022. PMID: 35086627 Free PMC article.
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Mohr-Holland E, Reuter A, Hughes J, Daniels J, Beko B, Makhanda G, De Avezedo V, Kock Y, Cox H, Furin J, Trivino Duran L, Isaakidis P, Ferlazzo G. Mohr-Holland E, et al. Among authors: kock y. Eur Respir J. 2020 Jul 23;56(1):2000837. doi: 10.1183/13993003.00837-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32703820 Free article. No abstract available.
Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa.
Reuter A, Beko B, Memani B, Furin J, Daniels J, Rodriguez E, Reuter H, Weich L, Isaakidis P, von der Heyden E, Kock Y, Mohr-Holland E. Reuter A, et al. Among authors: kock y. Trop Med Infect Dis. 2022 Jan 31;7(2):21. doi: 10.3390/tropicalmed7020021. Trop Med Infect Dis. 2022. PMID: 35202216 Free PMC article.
35 results